Mereo BioPharma Group plc Operating Income 2011-2026 | MREO

Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.

Formula

Operating profit = Revenue – Operating expenses

Features of the metric

Evaluates business efficiency
Shows how well the company controls its production and administrative costs.
Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies.
Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.

If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.

Annual Operating Income Mereo BioPharma Group plc

2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-20.9 M	-37.6 M	-39.5 M	-34.5 M	-45.3 M	-36.2 M	-	-	-	-	-

All numbers in GBP currency

Indicator range from annual reports

Maximum	Minimum	Average
-20.9 M	-45.3 M	-35.7 M

Operating Income of other stocks in the Biotechnology industry

Issuer	Operating Income	Price	% 24h	Market Cap	Country
BioNTech SE BNTX	15.3 B	$ 91.28	0.11 %	$ 27.2 B	Germany
MorphoSys AG MOR	-508 M	-	2.43 %	$ 254 M	Germany
Genfit SA GNFT	31.8 M	-	2.54 %	$ 160 B	France
Biophytis SA BPTS	-26.8 M	-	-13.47 %	$ 169 M	France
Midatech Pharma plc MTP	-7 M	-	-18.52 %	$ 27.3 M	Britain
Acorda Therapeutics ACOR	-265 M	-	-24.86 %	$ 820 K	USA
Advaxis ADXS	-36.3 M	-	-9.65 %	$ 45.9 M	USA
Adverum Biotechnologies ADVM	-139 M	-	-	$ 86.2 M	USA
Aeterna Zentaris AEZS	-8.67 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	-24 M	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	-210 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	-17.7 M	-	-	$ 26.5 M	USA
AIkido Pharma AIKI	-55.7 M	-	1.93 %	$ 17.4 M	USA
Akero Therapeutics AKRO	-285 M	-	-	$ 3.67 B	USA
CureVac N.V. CVAC	-412 M	-	-	$ 867 M	Germany
Akari Therapeutics, Plc AKTX	-17.3 M	$ 3.54	-20.81 %	$ 238 B	Britain
Akouos AKUS	-86.8 M	-	0.23 %	$ 488 M	USA
Allakos ALLK	-196 M	-	-	$ 28.6 M	USA
Allena Pharmaceuticals ALNA	-47.6 M	-	3.16 %	$ 1.9 M	USA
Alnylam Pharmaceuticals ALNY	502 M	$ 330.34	3.6 %	$ 43.3 B	USA
Alpine Immune Sciences ALPN	-58.1 M	-	-	$ 2.17 B	USA
Aileron Therapeutics ALRN	-50.6 M	-	10.36 %	$ 9.8 M	USA
AlloVir ALVR	-46.2 M	-	4.14 %	$ 49.1 M	USA
Evogene Ltd. EVGN	-31 M	$ 0.79	1.22 %	$ 27.9 M	Israel
Ampio Pharmaceuticals AMPE	-33.3 M	-	-11.43 %	$ 502 K	USA
argenx SE ARGX	-349 M	$ 748.25	0.25 %	$ 25 B	Niderland
Applied Molecular Transport AMTI	-127 M	-	-	$ 10.1 M	USA
Applied Therapeutics APLT	-64.5 M	-	-	$ 8.42 M	USA
Aptinyx APTX	-62.6 M	-	-39.0 %	$ 4.57 M	USA
AbbVie ABBV	15.1 B	$ 206.69	-1.01 %	$ 366 B	USA
Aquestive Therapeutics AQST	-71.1 M	$ 4.09	-0.97 %	$ 437 M	USA
Aravive ARAV	-70.8 M	-	-13.39 %	$ 1.45 M	USA
AbCellera Biologics ABCL	-217 M	$ 3.39	-3.69 %	$ 1.01 B	Canada
Arcturus Therapeutics Holdings ARCT	-76.3 M	$ 8.22	2.37 %	$ 225 M	Israel
Ardelyx ARDX	-41 M	$ 5.97	0.51 %	$ 1.44 B	USA
Genmab A/S GMAB	2.64 B	$ 27.75	0.91 %	$ 17.6 B	Danmark
Cerevel Therapeutics Holdings CERE	-447 M	-	-	$ 7.29 B	USA
Grifols, S.A. GRFS	595 M	$ 8.23	-0.12 %	$ 6.83 B	Spain
Akebia Therapeutics AKBA	23.5 M	$ 1.32	-4.35 %	$ 339 M	USA